Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10265482 | 1.00 | FGFR3 (0.66) | FGFR3KDR | |
| SCHEMBL556274 | 0.95 | FGFR3 (0.65) | FGFR3KDR | |
| SCHEMBL556275 | 0.95 | FGFR3 (0.65) | FGFR3KDR | |
| SCHEMBL557915 | 0.95 | FGFR3 (0.64) | FGFR3KDR | |
| SCHEMBL557916 | 0.95 | FGFR3 (0.64) | FGFR3KDR | |
| SCHEMBL557556 | 0.93 | FGFR3 (0.67) | FGFR3KDR | |
| SCHEMBL557555 | 0.93 | FGFR3 (0.67) | FGFR3KDR | |
| SCHEMBL629237 | 0.90 | FGFR3 (0.70) | FGFR3KDR | |
| SCHEMBL629236 | 0.90 | FGFR3 (0.70) | FGFR3KDR | |
| SCHEMBL556280 | 0.88 | FGFR3 (0.62) | FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419427-B1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | ASTEX THERAPEUTICS LTD (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-8481531-B2 | Bicyclic heterocyclyl derivatives as FGFR kinase inhibitors for therapeutic use | ASTEX THERAPEUTICS LTD (GB) | 2013-07-09 | — | — | US | disclosed |
| EP-2419427-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | Astex Therapeutics Ltd. (GB) | 2012-02-22 | — | — | EP | disclosed |
| US-20120035171-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-09 | — | — | US | disclosed |
| WO-2010119284-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | ASTEX THERAPEUTICS LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035171-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE | FGFR1, FGFR2, FGFR3 | FGFR3 3/4885KDR 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.